Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning


  • Aadi Bioscience receives FDA approval of Fyarro for treatment of patients with PEComa.
  • Fyarro (ABI-009) can be expanded upon in two specific gene pathways known as TSC1 and TSC2; this could bring access to thousands of new patients.
  • Further expansion of ABI-009 can be achieved with targeting other cancer subpopulations that have the mTOR pathway.
  • Aadi Bioscience had $161.4 million in cash and cash equivalents as of September 30, 2021; enough cash to fund operations into 2024.

Female scientist examining toxic liquid in laboratory.

skynesher/E+ via Getty Images

Aadi Bioscience (NASDAQ:AADI) received FDA approval for its drug Fyarro (ABI-009), which was approved to treat patients with a rare ultra sarcoma known as a PEComa. It is a small population of patients, but Fyarro is the first

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I’m currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

Leave a Reply

Your email address will not be published. Required fields are marked *